These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 8718419)

  • 1. Preclinical characteristics of gemcitabine.
    Plunkett W; Huang P; Gandhi V
    Anticancer Drugs; 1995 Dec; 6 Suppl 6():7-13. PubMed ID: 8718419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
    Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular pharmacology of gemcitabine.
    Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
    Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.
    Gandhi V; Mineishi S; Huang P; Yang Y; Chubb S; Chapman AJ; Nowak BJ; Hertel LW; Plunkett W
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):61-7. PubMed ID: 7481847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
    Huang P; Chubb S; Hertel LW; Grindey GB; Plunkett W
    Cancer Res; 1991 Nov; 51(22):6110-7. PubMed ID: 1718594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA.
    Gandhi V; Legha J; Chen F; Hertel LW; Plunkett W
    Cancer Res; 1996 Oct; 56(19):4453-9. PubMed ID: 8813140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
    Heinemann V; Hertel LW; Grindey GB; Plunkett W
    Cancer Res; 1988 Jul; 48(14):4024-31. PubMed ID: 3383195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.
    Sigmond J; Kamphuis JA; Laan AC; Hoebe EK; Bergman AM; Peters GJ
    Biochem Pharmacol; 2007 May; 73(10):1548-57. PubMed ID: 17324380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells.
    Ross DD; Cuddy DP
    Biochem Pharmacol; 1994 Oct; 48(8):1619-30. PubMed ID: 7980627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
    Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
    Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
    Iwasaki H; Huang P; Keating MJ; Plunkett W
    Blood; 1997 Jul; 90(1):270-8. PubMed ID: 9207462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
    Heinemann V; Xu YZ; Chubb S; Sen A; Hertel LW; Grindey GB; Plunkett W
    Cancer Res; 1992 Feb; 52(3):533-9. PubMed ID: 1732039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
    Heinemann V; Xu YZ; Chubb S; Sen A; Hertel LW; Grindey GB; Plunkett W
    Mol Pharmacol; 1990 Oct; 38(4):567-72. PubMed ID: 2233693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine: a critical nucleoside for cancer therapy.
    Gesto DS; Cerqueira NM; Fernandes PA; Ramos MJ
    Curr Med Chem; 2012; 19(7):1076-87. PubMed ID: 22257063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine: preclinical pharmacology and mechanisms of action.
    Plunkett W; Huang P; Searcy CE; Gandhi V
    Semin Oncol; 1996 Oct; 23(5 Suppl 10):3-15. PubMed ID: 8893876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay.
    Smid K; Van Moorsel CJ; Noordhuis P; Voorn DA; Peters GJ
    Int J Oncol; 2001 Jul; 19(1):157-62. PubMed ID: 11408937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.
    Jiang HY; Hickey RJ; Abdel-Aziz W; Malkas LH
    Cancer Chemother Pharmacol; 2000; 45(4):320-8. PubMed ID: 10755321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.